Сибирский онкологический журнал (Feb 2016)
Occurrence of BRCA1 and BRCA2 mutation in pancreatic cancer patients
- A. A. Kashintsev,
- G. A. Yanus,
- N. Yu. Kokhanenko,
- V. M. Moiseenko,
- M. D. Hanevich,
- L. D. Roman,
- A. G. Ievleva,
- A. P. Sokolenko,
- E. N. Suspitsin,
- A. I. Budovskiy,
- A. V. Togo,
- N. M. Volkov,
- R. V. Fadeev,
- M. S. Dinikin,
- A. K. Ivanova,
- K. G. Shostko,
- E. N. Imyanitov
Affiliations
- A. A. Kashintsev
- St.-Petersburg Pediatric Medical University
- G. A. Yanus
- St.-Petersburg Pediatric Medical University, N.N. Petrov Institute of Oncology, St.-Petersburg
- N. Yu. Kokhanenko
- St.-Petersburg Pediatric Medical University
- V. M. Moiseenko
- City Oncological Center, St.-Petersburg, S.M. Beresin Clinical Center, St.-Petersburg
- M. D. Hanevich
- City Oncological Hospital, St.-Petersburg
- L. D. Roman
- Leningrad Regional Oncological Hospital, St.-Petersburg
- A. G. Ievleva
- St.-Petersburg Pediatric Medical University, N.N. Petrov Institute of Oncology, St.-Petersburg
- A. P. Sokolenko
- St.-Petersburg Pediatric Medical University, N.N. Petrov Institute of Oncology, St.-Petersburg
- E. N. Suspitsin
- St.-Petersburg Pediatric Medical University, N.N. Petrov Institute of Oncology, St.-Petersburg
- A. I. Budovskiy
- N.N. Petrov Institute of Oncology, St.-Petersburg
- A. V. Togo
- St.-Petersburg Pediatric Medical University, N.N. Petrov Institute of Oncology, St.-Petersburg
- N. M. Volkov
- N.N. Petrov Institute of Oncology, St.-Petersburg, S.M. Beresin Clinical Center, St.-Petersburg
- R. V. Fadeev
- City Oncological Hospital, St.-Petersburg
- M. S. Dinikin
- City Oncological Hospital, St.-Petersburg
- A. K. Ivanova
- City Oncological Hospital, St.-Petersburg
- K. G. Shostko
- Leningrad Regional Oncological Hospital, St.-Petersburg
- E. N. Imyanitov
- St.-Petersburg Pediatric Medical University, N.N. Petrov Institute of Oncology, St.-Petersburg, I.I. Mechnikov North-West Medical University, St.-Petersburg
- Journal volume & issue
-
Vol. 0,
no. 5
pp. 39 – 44
Abstract
BRCA1 and BRCA2 may contribute in pancreatic cancer (PC) risk, however the selection criteria for BRCA1 testing are poorly defined. The analysis of Russian founder mutation BRCA1 5382insC in 150 PC patients identified 2 carriers. BRCA2 full-length sequencing of 8 DNA samples revealed 1 mutated allele (BRCA2 5197_5198delTC). All 3 carriers of BRCA1/2 mutations reported personal or familial history of BRCA-related cancers. Thus, BRCA1/2 testing is particularly
